Total
0
Shares
Medlab (ASX:MDC)- CEO, Sean Hall - The Market Herald
CEO, Sean Hall
Source: Medlab
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Biotech company Medlab Clinical (MDC) has been granted an Australian patent for its NanoCelle delivery platform
  • Essentially, NanoCelle delivers drug formulations via an oral spray
  • So far, product testing results have indicated the spray can lead to better absorption of the drugs, helping the formulation avoid ingested routes
  • It can also potentially lower drug dosages and reduce the side effects of some formulations
  • Medlab has also filed patent applications in other jurisdictions, such as the U.S., Europe and New Zealand
  • On the market this afternoon, Medlab is up 3.03 per cent, trading for 17 cents per share

Biotech company Medlab Clinical (MDC) has been granted an Australian patent for its NanoCelle delivery platform.

Essentially, NanoCelle delivers drugs via an oral spray. The device sprays the formulation into the Oro-buccal membrane, which is located along the lining of the cheek and the roof of the mouth.

So far, product testing results have indicated the spray can lead to better absorption of the drugs, helping the formulation avoid ingested routes. It can also potentially lower drug dosages and reduce the side effects of some formulations

Source: Medlab

Medlab CEO, Sean Hall, is pleased with the patent and says NanoCelle is a key feature in Medlab's leading drug, NanaBis.

"This is the first patent granted for our NanoCelle drug delivery platform, it is a huge validation of the science behind NanoCelle and its innovative mode of action," he said.

"NanoCelle is used to greatly improve drug solubility issues resulting in improved absorption, metabolism and utilisation, giving us [Medlab] many options to improve prescription and over the counter medicines," he added.

Medlab has also filed patent applications in the U.S., Europe, New Zealand, Canada, Hong Kong and Singapore.

On the market this afternoon, Medlab is up 3.03 per cent, trading for 17 cents per share at 2:06 pm AEST.

MDC by the numbers
More From The Market Herald
Oventus Medical (ASX:OVN) - Chairman, Sue MacLeman (centre left) - The Market Herald

" Oventus Medical (ASX:OVN) eyes $5M placement to strengthen balance sheet

Sleep apnoea specialist Oventus Medical (OVN) has received firm commitments to undertake a $5 million placement.
Telix Pharmaceuticals (ASX:TLX) - CEO, Dr. Christian Behrenbruch - The Market Herald

" Telix Pharmaceuticals (ASX:TLX) commences prostate cancer clinical trial

Telix Pharmaceuticals (TLX) has been given the green light to commence a phase three clinical trial of its targeted therapy candidate TLX591 in
Bod Australia (ASX:BDA) - CEO, Jo Patterson - The Market Herald

" Bod Australia (ASX:BDA) records highest ever month of MediCabilis sales

Bod Australia (BDA) has recorded its highest-ever month of medicinal cannabis sales, filling 1789 MediCabilis prescriptions in April.
Prescient Therapeutics (PTX) -CEO & Managing Director, Steven Yatomi - The Market Herald

" Prescient Therapeutics (ASX:PTX) signs new research agreement with Peter MacCallum Cancer Centre

Prescient Therapeutics (PTX) has announced a new research program with the Peter MacCallum Cancer Centre to advance its next-generation CAR-T programs.